GlassScriptPhysician profile
Thomas Lee Aung
NPI 1679515530
$1,384.97
in general payments reported to CMS, 2019-2025
24 companies · $55.53 in 2025
The $55.53 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $137 · 2021: $31.85 · 2023: $19.34 · 2024: $21.09 · 2025: $55.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $166.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $163.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $155.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $114.71 | 2019 | |
| Eisai INC. | $80.91 | 2019 | |
| Janssen Biotech, INC. | $69.10 | 2021-2025 | Tecvayli, Darzalex |
| Amgen INC. | $68.94 | 2019-2020 | |
| Pfizer INC. | $57.36 | 2019-2020 | |
| Verastem, INC. | $56.71 | 2019 | |
| Genentech USA, INC. | $55.31 | 2019 | |
| Astellas Pharma US INC | $53.35 | 2019-2020 | |
| Genzyme Corporation | $48.76 | 2019 | |
| Lilly USA, LLC | $40.08 | 2019 | |
| Servier Pharmaceuticals LLC | $37.62 | 2025 | |
| Amag Pharmaceuticals, INC. | $30.93 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $28.33 | 2019 | |
| Merck Sharp & Dohme LLC | $27.84 | 2019 | |
| Rigel Pharmaceuticals, INC. | $25.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.83 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.40 | 2019 | |
| Sobi, INC | $21.09 | 2024 | |
| Taiho Oncology, INC. | $14.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.57 | 2019 | |
| Dova Pharmaceuticals | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Aung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.